Home › Research › Drug development
Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study
Dangpiaei S, Kamal KM, Shoair OA, Al-Mamun MA.. Journal of managed care & specialty pharmacy, 2026-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage. Real-world evidence (RWE) studies are critically warranted to evaluate the associated risks of ARIA and health care resource utilization (HRU) with monoclonal treatments compared with existing nonmonoclonal (eg, donepezil, memantine and rivastigmine) treatments. Objective To evaluate the risk of ARIA in patients receiving monoclonal vs nonmonoclonal treatments.
What this study adds
Evidence grade: High
The record lists 240 participants. It also aimed to investigate health care resource utilization, including emergency department and inpatient visits, between the two groups. Reported effect size: 47.08%; 47.29%; 55.42%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dangpiaei, S., Kamal, K. M., Shoair, O. A., & Al-Mamun, M. A. (2026). Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. Journal of managed care & specialty pharmacy. https://doi.org/10.18553/jmcp.2026.32.4.470
Vancouver
Dangpiaei S, Kamal KM, Shoair OA, Al-Mamun MA. Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. Journal of managed care & specialty pharmacy. 2026. doi:10.18553/jmcp.2026.32.4.470. PMID: 41885326.
BibTeX
@article{dangpiaei2026-41885326,
author = {Dangpiaei, S. and Kamal, K. M. and Shoair, O. A. and Al-Mamun, M. A.},
title = {{Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study}},
journal = {Journal of managed care \& specialty pharmacy},
year = {2026},
doi = {10.18553/jmcp.2026.32.4.470},
pmid = {41885326},
url = {https://doi.org/10.18553/jmcp.2026.32.4.470}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Real-world evidence (RWE) studies are critically warranted to evaluate the associated risks of ARIA and health care resource utilization (HRU) with monoclonal treatments compared with existing nonmonoclonal (eg, donepezil, memantine and rivastigmine) treatments.
- Objective To evaluate the risk of ARIA in patients receiving monoclonal vs nonmonoclonal treatments.
- The secondary aim was to investigate the HRUs including emergency department (ED) and inpatient visits between the 2 groups.
- Methods We conducted a retrospective study using a large electronic health record dataset.
Why it matters
This real-world evidence study was designed to evaluate the risk of amyloid-related imaging abnormalities, which can include brain swelling or hemorrhage, in patients receiving monoclonal antibodies such as aducanumab, lecanemab and donanemab compared with nonmonoclonal treatments. It also aimed to investigate health care resource utilization, including emergency department and inpatient visits, between the two groups.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants240
- Effect size47.08%; 47.29%; 55.42%
- Evidence strengthHigh
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of managed care & specialty pharmacy) |
| Journal's citation record | 0 / 4 | Journal of Managed Care & Specialty Pharmacy: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 240 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Mohammad A. Al-Mamun holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | West Virginia University: institution h-index 677 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41885326) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 37 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.18553/jmcp.2026.32.4.470
- PubMed: 41885326
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.